BGA
PGNX

Belmont Global Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Belmont Global Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-75,000
Closed -$307K – 154
2014
Q1 		$307K Buy
+75,000
New +$384K 0.26% 86

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Belmont Global Advisors's PGNX Position: Q2 2014 in Review

Belmont Global Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2014, closing a stake of 75,000 shares — an estimated $307K sold.

Belmont Global Advisors first reported a position in PGNX in Q1 2014 and held it in 1 quarter. The position peaked at $307K in Q1 2014. 76 funds tracked by Wall St. Rank hold PGNX as of Q2 2014.

  • Belmont Global Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Belmont Global Advisors sold 75,000 Progenics Pharmaceuticals Inc shares in Q2 2014, an estimated $307K.
  • Belmont Global Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 1 quarter.
  • Belmont Global Advisors's Progenics Pharmaceuticals Inc position peaked at $307K in Q1 2014.
  • 76 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2014.

Based on Belmont Global Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.